Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Allying on ALRN-6924
December 2018
SHARING OPTIONS:

WATERTOWN, Mass.—Aileron Therapeutics and the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have united under an agreement to conduct an open-label, multi-center, pediatric Phase 1 clinical trial of Aileron’s lead drug candidate, ALRN-6924. The trial will evaluate ALRN-6924 in children with solid tumors, and ALRN-6924 plus cytarabine in children with acute leukemia, in two dose-escalation cohorts, with a third cohort being biomarker-enriched.
 
“MDMX and MDM2 play a role in many cancers, and our dual inhibitor of MDMX and MDM2, ALRN-6924, has shown in clinical trials that it can achieve responses in cancer patients,” said Dr. Manuel Aivado, CEO of Aileron Therapeutics. “We are thankful for the opportunity to provide ALRN-6924 to relapsed and refractory pediatric patients in an effort to improve outcomes for these children.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.